Navigation Links
IRIDEX Reports Third Quarter 2008 Financial Results
Date:11/4/2008

MOUNTAIN VIEW, Calif., Nov. 4 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the third quarter ended September 27, 2008.

Revenue for the third quarter of 2008 was $12.0 million, an 11.7% decrease from the $13.6 million reported for the third quarter of 2007. The Company recorded net loss of $0.2 million or $(0.03) per diluted share for the third quarter of 2008, an improvement over the net loss of $1.2 million or $(0.15) per diluted share reported in the third quarter of 2007.

Ophthalmology revenues were $8.2 million in the third quarter of 2008, a 4.0% increase from $7.9 million in the comparable period of 2007. Comparing third quarter 2008 vs. 2007, domestic ophthalmology revenues increased 17.0% to $5.3 million, international ophthalmology revenues decreased 13.2% to $2.9 million and ophthalmology recurring revenues, consisting of disposable products and service, increased to 49.3% of our total ophthalmology revenues compared to 46.9% for the comparable period of 2007.

Total aesthetics revenues were $3.8 million in the third quarter of 2008, a decrease of 33.4% from $5.7 million in the comparable period of 2007. In the third quarter of 2008, domestic aesthetics revenues decreased $0.6 million to $2.1 million and international aesthetics revenues decreased $1.3 million to $1.7 million when compared to the same period in 2007.

Gross profit for the third quarter of 2008 was $5.0 million, compared with $6.2 million for the third quarter of 2007. Gross margins were 41.6% and 45.6%, respectively. Operating expenses for the third quarter 2008 were $5.2 million compared with $7.2 million for 2007.

Mr. Theodore A. Boutacoff, President and CEO stated, "Operationally we continue to make progress towards financial stability as demonstrated by the substantial improvement in our quarterly operating performance year over year, reducing loss from operations from $1.1 million in the third quarter of 2007 to a loss of $0.2 million in the third quarter of 2008, primarily due to reductions in operating expenses. Furthermore, we can report that we have met all of our obligations to AMS which has been a major cash burden for us during the first 9 months of 2008. In total, including principle, interest and payments for the non-cancelable purchase orders we paid AMS $6.3 million in 2008, with $2.0 million of that being during the third quarter."

Cash and cash equivalents were $3.0 million as of September 27, 2008 down from $4.1 million as of June 28, 2008. However, working capital increased to $9.4 million from $8.9 million over the same period. Cash used in operations for the third quarter was $1.0 million, which includes repaying the remaining amounts owed to AMS, and our bank debt as of September 27, 2008 was $6.0 million, which was unchanged from the balance as of June 28, 2008.

Conference Call

IRIDEX management will conduct a conference call later today, Tuesday, November 4, 2008 at 5:00 p.m. Eastern Time. Interested parties may access the live conference call via telephone by dialing (866) 250-4375 (US) or (303) 262-2161 (International), or by visiting the Company's website at http://www.iridex.com. A telephone replay will be available beginning on Tuesday, November 4, 2008 through Tuesday, November 11, 2008 by dialing (800) 405-2236 (US) or (303) 590-3000 (International) and entering Passcode 11122023#. In addition, later today an archived version of the webcast will be available on the Company's website at http://www.iridex.com.

About IRIDEX

IRIDEX Corporation is a leading worldwide provider of therapeutic based laser systems, disposable laser probes and delivery devices to treat eye diseases in ophthalmology and skin disorders in the aesthetics market. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 100 independent distributors into 107 countries. For further information, visit the Company's website at http://www.iridex.com.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Act of 1934, as amended, relating to the Company's financial stability. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended December 29, 2007 and our Quarterly Report on Form 10-Q for the third quarter ended September 27, 2008 filed with the Securities and Exchange Commission. Forward- looking statements contained in this announcement are made as of this date and will not be updated.

IRIDEX Corporation

Condensed Consolidated Statements of Operations

(In thousands, except per share data)

(unaudited)

Three Months Ended Nine Months Ended

September September September September

27, 29, 27, 29,

2008 2007 2008 2007

Revenues $11,987 $13,575 $36,383 $41,390

Cost of revenues 6,997 7,390 21,257 23,412

Gross profit 4,990 6,185 15,126 17,978

Operating expenses:

Research and development 972 1,319 2,995 4,636

Selling, general and

administrative 4,248 5,920 13,356 21,740

Total operating expenses 5,220 7,239 16,351 26,376

Loss from operations (230) (1,054) (1,225) (8,398)

Legal settlement - - 800 2,500

Interest and other

expense, net (54) (184) (426) (603)

Loss before income taxes (284) (1,238) (851) (6,501)

Benefit (provision)

for income taxes 35 - (16) -

Net loss $(249) $(1,238) $(867) $(6,501)

Net loss per share -

basic and diluted $(0.03) $(0.15) $(0.10) $(0.80)

Shares used in computing

net loss per share -

basic and diluted 8,824 8,218 8,824 8,165

IRIDEX Corporation

Condensed Consolidated Balance Sheets

(In thousands)

(Unaudited)

September 27, December 29,

2008 2007

Assets (unaudited)

Current Assets:

Cash and cash equivalents $2,974 $5,809

Restricted cash - 3,800

Accounts receivable, net 9,215 8,876

Inventories, net 13,527 15,967

Prepaids and other current assets 1,264 1,051

Total current assets 26,980 35,503

Property and equipment, net 1,128 1,621

Goodwill 3,239 3,239

Other intangible assets, net 4,185 5,944

Other long term assets 224 347

Total assets 35,756 46,654

Liabilities and Stockholders' Equity

Current Liabilities:

Accounts payable $2,593 $2,887

Bank line of credit 6,000 4,863

Accrued compensation 1,680 2,024

Accrued expenses 3,235 7,809

Accrued warranty 1,258 1,895

Deferred revenue 2,805 3,350

Bank term loan-current portion - 5,016

Total current liabilities 17,571 27,844

Stockholders' Equity:

Convertible preferred stock, $.01

par value:

Authorized: 2,000,000 shares;

Issued and outstanding: 500,000

shares in 2008 and 2007 5 5

Common Stock, $.01 par value:

Authorized: 30,000,000 shares; Issued

and outstanding: 8,824,301 shares in

2008 and 2007 89 89

Additional paid-in capital 39,087 38,695

Accumulated other comprehensive loss (238) (88)

Treasury stock, at cost (430) (430)

Accumulated deficit (20,328) (19,461)

Total stockholders' equity 18,185 18,810

Total liabilities and stockholders'

equity $35,756 $46,654


'/>"/>
SOURCE IRIDEX Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. IRIDEX Announces Third Quarter 2008 Conference Call and Release Date
2. IRIDEX Reports First Quarter 2008 Financial Results
3. IRIDEX Announces First Quarter 2008 Conference Call and Release Date
4. IRIDEX Reports Fourth Quarter and Full Year 2007 Financial Results
5. IRIDEX Announces Fourth Quarter and Full Year 2007 Conference Call and Release Date
6. IRIDEX Reports Third Quarter Financial Results
7. IRIDEX Announces Third Quarter 2007 Conference Call and Release Date
8. Theodore A. Boutacoff Appointed President & CEO of IRIDEX
9. James B. Hawkins Appointed to IRIDEX Board of Directors
10. IRIDEX Appoints Burr, Pilger & Mayer New Independent Auditor
11. William Moore Appointed to IRIDEX Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... 2016 , ... Center for Autism and Related Disorders (CARD) Portland today announced ... disorder (ASD) and other developmental disabilities. The group, which is being launched with the ... the opportunity to share stories and advice, seek help, and continue their education on ...
(Date:12/2/2016)... ... 2016 , ... U.S. Surgeon General, Dr. Vivek Murthy, graces the cover of ... was inspired to practice medicine at an early age by his father, who was ... diagnoses and prescribing medicine,” he states. “It is about building relationships with people; relationships ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... two ostomy patients, standing as living proof that attitude and determination can combine ... and issues that spike around the holidays. This campaign will offer patients a ...
(Date:12/2/2016)... ... December 02, 2016 , ... More than half of American teens report losing ... report speaking with their child about sex related topics, less than 60 percent spoke ... proud to announce the launch of its second edition of the “Sexual Wellness” campaign, ...
(Date:12/2/2016)... ... 02, 2016 , ... CloudLIMS.com, a class-leading provider of Laboratory ... CloudLIMS Lite helps biobanks, clinical, research and testing laboratories keep track of their ... version is a faster and a more efficient product, allowing batch processing of ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... -- UCB is pleased to announce that 12 scientific abstracts have ... American Epilepsy Society (AES) Annual Meeting, which takes place ... USA. 1-12 Data being presented include ... ® (lacosamide) CV and BRIVIACT ® (brivaracetam) CV. ... state of the union of epilepsy care and antiepileptic drugs ...
(Date:12/2/2016)... -- Allergan plc (NYSE: AGN ), a leading ... announced Accelerated Share Repurchase (ASR) Program. Logo - ... , ... announced, the Company entered into a variable tenor ASR arrangement ... $10 billion of its ordinary shares. Approximately 40.5 million shares ...
(Date:11/30/2016)... , Nov 30, 2016 Research and ... Intracranial Pressure Monitoring Devices 2017 - MedCore" report to their offering. ... , , ... brain and the skull. In healthy individuals, it is circulated though the ... are cases where the amount of CSF surrounding the brain changes significantly. ...
Breaking Medicine Technology: